Arnatar Therapeutics
PrivateLast Round
Series A
Apr 8, 2024
Total Funding Raised
$118.45M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Arnatar Therapeutics is a biotechnology company that develops RNA-based therapies using its proprietary DARGER platform to silence disease drivers or restore protein function for the treatment of cardiometabolic, liver, kidney, and central nervous system diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Arnatar Therapeutics Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Arnatar Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Apr 8, 2024 | ||||
| Seed | Sep 19, 2022 |
Key People
Founding team and executive leadership
Arnatar Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Jifeng Ventures | Series A |
| New Alliance Capital | Series A |
| Legend Star | Series A |
| Bencao Capital | Series A |
| Eight Roads Ventures | Series A |
| Transfar Group | Series A |
| Huajin Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 30, 2026
Grew 60% QoQ from 10 to 16 employees.
- May 22, 2026
Grew 40% QoQ from 10 to 14 employees.
Arnatar Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Arnatar Therapeutics's valuation, stock price, and market status.